Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Paspalum notatum pollen is a biological allergen extract derived from the pollen of Paspalum notatum, commonly known as Bahia grass. This grass pollen is a significant cause of type I hypersensitivity reactions, such as allergic rhinitis and other respiratory allergies, particularly in subtropical regions like the southeastern United States. [1, 8] The extract contains several allergenic proteins that elicit skin-test-positive reactions in sensitized individuals. [1] It is used for both the diagnosis of Bahia grass pollen allergy through skin testing (percutaneous or intradermal) and for treatment via allergen immunotherapy (subcutaneous injections). [2] The diagnostic use relies on the extract's ability to trigger a localized allergic reaction (wheal and flare) upon introduction into the skin of a sensitized person. [2] Allergen immunotherapy involves administering gradually increasing doses of the extract to induce immunological tolerance and reduce the severity of allergic symptoms upon natural exposure. [15] Multiple companies, including Hollister-Stier Labs, LLC, ALK-Abello, Inc., and Greer Laboratories, Inc., manufacture and supply this allergenic extract. [10]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Paspalum notatum pollen.